Navigation Links
CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings

ll be made available on CuraGen's website at http://www.curagen.com, or by emailing . info@curagen.com

About Belinostat

Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including 5-FU, carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade(R) (bortezomib) for Injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes and have been shown to: arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote

differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents.

Intravenous belinostat is currently being evaluated in multiple clinical trials as a potential treatment for multiple myeloma, T- and B-cell lymphomas, AML, mesothelioma, liver, colorectal, ovarian cancers, either alone or in combination with anti-cancer therapies. An oral formulation of belinostat is also being evaluated in a Phase I clinical trial for patients with advanced solid tumors. In August 2004, CuraGen signed a Clinical Trials Agreement with the NCI under which the NCI will sponsor several clinical trials to investigate belinostat for the treatment of various cancers, both as a single- agent and in combination chemotherapy regimens. In May 2005, TopoTarget announced the signing of a Cooperative Research and Development Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies on belinostat in order to better understand its anti-tumor activity and to provide supporting information for clinical trials.

About CuraGen

CuraGen Corporati
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:12/15/2009)... SINGAPORE, Dec. 15 ... that it has completed the previously announced ... manufacturer of disposable medical devices ranging from ... surgery. Through its medical segment, Flextronics provides ... device, medical equipment, and pharmaceutical customers. Terms ...
(Date:12/15/2009)... WASHINGTON, Dec. 15 Today,s ... Sack, "Plan for Kidney Drugs Spurs Division," illustrates ... result in kidney patients continuing to be deprived ... 36-month Medicare program limit. ,, As Congress is ... to preserve the lives of transplant kidney recipients, ...
(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... Analysis and Market Forecasts to 2015 ... ,, Systemic Lupus Erythematosus - Drug ... 2015 ,, Summary ,, ...
Breaking Medicine Technology:Flextronics Completes SloMedical Acquisition 2AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate 2Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 2Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 3Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 4Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 5Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 6Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 7Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 8RAM Technologies Named to Philadelphia Business Journals List of Top Tech Employers 58994 1RAM Technologies Named to Philadelphia Business Journals List of Top Tech Employers 58994 2Amnis Begins Shipment of New ImageStreamX Imaging Flow Cytometers 5275 1Amnis Begins Shipment of New ImageStreamX Imaging Flow Cytometers 5275 2Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350 5272 1Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350 5272 2
... 29 Sanofi-aventis,announced today that the U.S. Food ... origin] injection) to improve glycemic,control in children (4 ... approval of Apidra(R) for pediatric use is based ... active control study of Apidra(R) in,comparison with insulin ...
... results to be presented at 2008 ICAAC/IDSA ... Sequella, Inc., a,clinical-stage biopharmaceutical company focused ... epidemic potential, announces the,successful demonstration of synergistic ... resulting from in vitro combination,studies of Sequella ...
Other Medicine Technology:FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 2FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 3FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 4FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 5Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207 2
(Date:12/15/2009)... Dec. 15 The new compact LifeSpan TR200 ... www.LifeSpanFitness.com ), was highly praised by treadmill ... for 2010. The compact TR200 folding treadmill received awards ... Treadmill under $1000. ,, The compact LifeSpan TR200 ... small workout spaces. "This category buster is a very ...
(Date:12/15/2009)... ARBOR, Mich. A new study links chronic obstructive ... that act as sentinels to activate the body,s immune ... Affairs research adds to growing awareness of the immune ... that affects more than 12 million Americans with wheezing, ... immune factors is key if doctors are to find ...
(Date:12/15/2009)... developmental changes increases risk in teens, study suggests , , ... overweight or obese increases the risk of obstructive sleep ... true for younger children, Australian researchers have found. , ... 2 to 18, who were referred for evaluation of ... that among those aged 12 and older the risk ...
(Date:12/15/2009)... for injury when doctors decide benefits of imaging outweigh ... MRI scans can pose a serious risk to people ... Drug Administration researchers exposed pacemakers to a simulated MRI ... at the tip of the pacemaker lead, where it ... The exposure to MRI magnetic pulses caused certain pacemakers ...
(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... the U.S. and its International Trade ... http://www.reportlinker.com/p0167482/In-Vitro-Diagnostic-Substance-Manufacturing-Industry-in-the-US-and-its-International-Trade-[Q4-2009-Edition].html ,, The newly published ... provides the latest market research on ...
Breaking Medicine News(10 mins):Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2Health News:Immune cell activity linked to worsening COPD 2Health News:Immune cell activity linked to worsening COPD 3Health News:Puberty May Trigger Sleep Apnea in Overweight Kids 2Health News:Patients With Pacemakers Should Avoid MRI Scans 2Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 2Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 3Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 4Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 5Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 6Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 7Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 8
... WASHINGTON, March 13 A former Department of Veterans ... a jury on four counts of honest services mail ... making a false statement to agency officials, Acting Assistant ... E. Nahmias of the Northern District of Georgia announced. ...
... , "Listen to caregivers and be willing to collaborate ... can either master it or it can master you."ALEXANDRIA, ... the cusp of massive health care reform, the American ... to leading the charge to control costs, improve quality, ...
... new Rice University report released yesterday, exactly six months ... that people did not practice the lessons learned from ... of Harris County residents say they would evacuate if ... significant potential increase over the 24 percent of residents ...
... is more difficult to recognize and treat epilepsy in ... of Deutsches rzteblatt International ( Dtsch Arztebl ... the Epilepsy Center of Johannes Gutenberg University in Mainz, ... the therapeutic options. , It is often not ...
... EXTON, Pa., March 13 Kensey Nash Corporation (Nasdaq: ... the Sidoti Thirteenth Annual New York Emerging Growth Institutional ... City on Tuesday, March 24, 2009.Joseph W. Kaufmann, Kensey ... approximately 11:35 a.m. (ET). The presentation materials will ...
... Calif., March 13 Transcept Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of proprietary products that address ... announced it will report results for its fourth quarter ... A conference call to review the results will begin ...
Other Medicine News:Health News:Jury Convicts Former Social Worker of Defrauding The Department of Veterans Affairs and Obstructing Justice 2Health News:APTA's Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change 2Health News:APTA's Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change 3Health News:APTA's Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change 4Health News:Rice report shows lessons from Hurricane Rita not practiced during Ike 2Health News:Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results 2Health News:Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: